Clopidrax 75mg Side effects

• Side effects of Clopidrax 75mg in details
• Clopidrax 75mg contraindications
• Clopidrax 75mg reviews

What are the possible side effects of Clopidrax 75mg?

Get emergency medical help if you have any signs of an allergic reaction to Clopidrax 75mg: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using Clopidrax 75mg and call your doctor at once if you have any of these serious side effects:

• nosebleed or other bleeding that will not stop;

• bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;

• pale skin, weakness, fever, or jaundice (yellowing of the skin or eyes);

• easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;

• heart attack symptoms--chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating; or

• signs of a stroke--sudden numbness or weakness (especially on one side of the body), sudden severe headache, slurred speech, problems with vision or balance.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side effects of Clopidrax 75mg in details

Clinical Studies Experience: Clopidrax 75mg has been evaluated for safety in >44,000 patients, including >12,000 patients treated for ≥1 year. The clinically relevant adverse effects observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed as follows. Clopidrax 75mg 75 mg/day was well tolerated compared to ASA 325 mg/day in CAPRIE. The overall tolerability of Clopidrax 75mg in this study was similar to ASA, regardless of age, gender and ethnicity.

Haemorrhagic Disorders: In CAPRIE, in patients treated with either Clopidrax 75mg or ASA, the overall incidence of any bleeding was 9.3%. The incidence of severe cases was 1.4% for Clopidrax 75mg and 1.6% for ASA. In patients that received Clopidrax 75mg, gastrointestinal bleeding occurred at a rate of 2% and required hospitalisation in 0.7%. In patients that received ASA, the corresponding rates were 2.7% and 1.1%, respectively.

The overall incidence of other bleedings was higher in patients that received Clopidrax 75mg compared to ASA (7.3% vs 6.5%). However, the incidence of severe events was similar in both treatment groups (0.6% vs 0.4%). The most frequently reported events in both treatment groups were: Purpura/bruising and epistaxis. Other less frequently reported events were haematoma, haematuria and eye bleeding (mainly conjunctival).

The incidence of intracranial bleeding was 0.4% in patients that received Clopidrax 75mg and 0.5% for patients that received ASA.

In CURE, the administration of Clopidrax 75mg + ASA as compared to placebo + ASA was not associated with a statistically significant increase in life-threatening bleeds (event rates 2.2% vs 1.8%) or fatal bleeds (0.2% vs 0.2%), but the risk of major, minor and other bleedings was significantly higher with Clopidrax 75mg + ASA: Major bleeds (3.7% Clopidrax 75mg + ASA vs 2.7% placebo + ASA), non-life-threatening major bleeds (1.6% Clopidrax 75mg + ASA vs 1% placebo + ASA), primarily gastrointestinal and at puncture sites, and minor bleeds (5.1% Clopidrax 75mg + ASA vs 2.4% placebo + ASA). The incidence of intracranial bleeding was 0.1% in both groups.

The major bleeding event rate for Clopidrax 75mg + ASA was dose-dependent on ASA (<100 mg: 2.6%; 100-200 mg: 3.5%; >200mg: 4.9%) as was the major bleeding event rate for placebo + ASA (<100 mg: 2%; 100-200 mg: 2.3%; >200 mg: 4%).

The risk of bleeding (life-threatening, major, minor, other) decreased during the course of the trial: 0-1 months [Clopidrax 75mg: 599/6259 (9.6%); placebo: 413/6303 (6.6%)], 1-3 months [Clopidrax 75mg: 276/6123 (4.5%); placebo: 144/6168 (2.3%)], 3-6 months [Clopidrax 75mg: 228/6037 (3.8%); placebo: 99/6048 (1.6%)], 6-9 months [Clopidrax 75mg: 162/5005 (3.2%); placebo: 74/4972 (1.5%)], 9-12 months [Clopidrax 75mg: 73/3841 (1.9%); placebo: 40/3844 (1%)].

There was no excess in major bleeds within 7 days after coronary bypass graft surgery in patients who stopped therapy >5 days prior to surgery (4.4% Clopidrax 75mg + ASA vs 5.3% placebo + ASA). In patients who remained on therapy within 5 days of bypass graft surgery, the event rate was 9.6% for Clopidrax 75mg + ASA and 6.3% for placebo + ASA.

In CLARITY, there was an overall increase in bleeding in the Clopidrax 75mg + ASA group (17.4%) versus the placebo + ASA group (12.9%). The incidence of major bleeding was similar between groups (1.3% vs 1.1% for the Clopidrax 75mg + ASA and the placebo + ASA groups, respectively). This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy. The incidence of fatal bleeding (0.8% vs 0.6% in the Clopidrax 75mg + ASA and the placebo + ASA groups, respectively) and intracranial hemorrhage (0.5% vs 0.7% in the Clopidrax 75mg + ASA and the placebo + ASA groups, respectively) was low and similar in both groups.

In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleedings was low and similar in both groups (0.6% vs 0.5% in the Clopidrax 75mg + ASA and the placebo + ASA groups, respectively).

In ACTIVE-A, the rate of major bleeding was greater in the Clopidrax 75mg + ASA group than in the placebo + ASA group (6.7% vs 4.3%). Major bleeding was mostly of extracranial origin in both groups (5.3% in the Clopidrax 75mg + ASA group; 3.5% in the placebo + ASA group), mainly in the gastrointestinal tract (3.5% vs 1.8%). There was an excess of intracranial bleeding in the Clopidrax 75mg + ASA treatment group compared to the placebo + ASA group (1.4% vs 0.8%, respectively). There was no statistically significant difference in the rates of fatal bleeding and hemorrhagic stroke (0.8% and 0.6%, respectively) between groups.

Haematological Disorders: In CAPRIE, severe neutropenia (<0.45 x 10⁹/L) was observed in 4 patients (0.04%) that received Clopidrax 75mg and 2 patients (0.02%) that received ASA. Two of the 9599 patients who received Clopidrax 75mg and none of the 9586 patients who received ASA had neutrophil counts of zero.

One case of aplastic anaemia occurred on Clopidrax 75mg treatment.

The incidence of severe thrombocytopenia (<80 x 10⁹/L) was 0.2% on Clopidrax 75mg and 0.1% on ASA; very rare cases of platelet count ≤30 g/L have been reported.

In CURE and CLARITY, the number of patients with thrombocytopenia or neutropenia was similar in both groups.

Other clinically relevant adverse drug reactions pooled from CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies with an incidence >0.1% as well as all serious and relevant adverse drug reactions are listed as follows.

The following CIOMS frequency rating is used: Very common (≥10%); common (≥1 and <10%); uncommon (≥0.1 and <1%); rare (≥0.01 and <0.1%); very rare (<0.01%); unknown (cannot be estimated from available data).

Central and Peripheral Nervous System Disorders: Uncommon: Headache, dizziness and paraesthesia. Rare: Vertigo.

Gastrointestinal System Disorders: Common: Dyspepsia, abdominal pain, diarrhoea. Uncommon: Nausea, gastritis, flatulence, constipation, vomiting, gastric and duodenal ulcer.

Platelet, Bleeding and Clotting Disorders: Uncommon: Increased bleeding time and decreased platelets.

Skin and Appendages Disorders: Uncommon: Rash and pruritus.

White Cell and RES Disorders: Uncommon: Leucopenia, decreased neutrophils and eosinophilia.

Post-Marketing Experience: Bleeding is the most common reaction reported in the post-marketing experience and was mostly reported during the 1st month of treatment.

Bleeding: Some cases were reported with fatal outcome (especially intracranial, gastrointestinal and retroperitoneal haemorrhage); serious cases of skin bleeding (purpura), musculoskeletal bleeding (haemarthrosis, haematoma), eye bleeding (conjunctival, ocular, retinal), epistaxis, respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), haematuria and haemorrhage of operative wound have been reported; cases of serious haemorrhage have been reported in patients taking Clopidrax 75mg concomitantly with ASA or Clopidrax 75mg with ASA and heparin.

Frequencies for the following adverse reactions are not known (cannot be estimated form available data).

Blood and Lymphatic System Disorders: Serious cases of bleeding, mainly skin, musculoskeletal, eye (conjunctival, ocular, retinal) and respiratory tract bleeding, epistaxis, haematuria and haemorrhage of operative wound; cases of bleeding with fatal outcome (especially intracranial, gastrointestinal and retroperitoneal haemorrhage); agranulocytosis, aplastic anaemia/pancytopenia, TTP, acquired haemophilia A.

Immune System Disorders: Anaphylactoid reactions, serum sickness; cross-reactive drug hypersensitivity among thienopyridines (eg, ticlopidine, prasugrel).

Psychiatric Disorders: Confusion, hallucinations.

Nervous System Disorder: Taste disturbances.

Vascular Disorders: Vasculitis, hypotension.

Respiratory, Thoracic and Mediastinal Disorders: Bronchospasm, interstitial pneumonitis, eosinophilic pneumonia.

Gastrointestinal Disorders: Colitis (including ulcerative or lymphocytic colitis), pancreatitis, stomatitis.

Hepatobiliary Disorders: Hepatitis, acute liver failure.

Skin and Subcutaneous Tissue Disorders: Maculopapular, erythematous or exfoliative rash, urticaria, pruritus, angioedema, bullous dermatitis (erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic (DRESS), eczema, lichen planus.

Musculoskeletal, Connective Tissue and Bone Disorders: Arthralgia, arthritis, myalgia.

Renal and Urinary Disorders: Glomerulopathy.

General Disorders and Administration Site Conditions: Fever.

Investigations: Abnormal liver function test, increased blood creatinine.

What is the most important information I should know about Clopidrax 75mg?

• Clopidrax 75mg may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Clopidrax 75mg with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
• Thrombotic thrombocytopenic purpura (TTP) is a serious, possibly fatal, condition that has occurred in patients who take Clopidrax 75mg. It has sometimes occurred after taking Clopidrax 75mg for short periods of time (eg, less than 2 weeks). Seek immediate medical attention if you have pale skin; purple skin patches; symptoms of hemolytic anemia (eg, unusual tiredness or weakness, fever or chills, stomach or back pain, yellowing of the eyes or skin); or unusual bruising or bleeding.
• Clopidrax 75mg may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.
• Tell your doctor or dentist that you take Clopidrax 75mg before you receive any medical or dental care, emergency care, or surgery. You may need to stop Clopidrax 75mg before you have certain types of surgery.
• Clopidrax 75mg must be converted in the body for it to work. This conversion does not occur as well in some people (about 2% of white patients, 4% of black patients, and 14% of Chinese patients), and the medicine may not work as well in these patients. Your doctor may perform a test to check how well your body is able to convert Clopidrax 75mg. Talk with your doctor for more information.
• Clopidrax 75mg should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.
• PREGNANCY and BREAST-FEEDING: If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Clopidrax 75mg while you are pregnant. It is not known if Clopidrax 75mg is found in breast milk. Do not breast-feed while taking Clopidrax 75mg.

Clopidrax 75mg contraindications

Clopidrax 75mg should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Clopidrax 75mg is contraindicated in patients with pheochro-mocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumor. Such hypertensive crises may be controlled by phen-tolamine.

Clopidrax 75mg is contraindicated in patients with known sensitivity or intolerance to the drug.

Clopidrax 75mg should not be used in epileptics or patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of seizures or extrapyramidal reactions may be increased.

References

1. DTP/NCI. "clopidogrel: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
2. European Chemicals Agency - ECHA. "Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (αS)-: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
3. HSDB. "CLOPIDOGREL". https://toxnet.nlm.nih.gov/cgi-bin/s... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Clopidrax 75mg are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clopidrax 75mg. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 8 here

Information checked by Dr. Sachin Kumar, MD Pharmacology